Survival Benefit with Low-Dose Nivolumab Regimen in Advanced SCCHN

Survival Benefit with Low-Dose Nivolumab Regimen in Advanced SCCHN

Based on improved survival and favorable toxicity profiles, immunotherapy with anti-PD-1 agents (pembrolizumab, nivolumab) has become the standard of care in recurrent/metastatic...

New Oncology Guidelines Worth Reading

New Oncology Guidelines Worth Reading

Recently, three new guidelines related to oncology have been issued by major European and American medical associations to help clinicians provide the...

New FDA Approvals for Cancer Treatment in September 2022

New FDA Approvals for Cancer Treatment in September 2022

In September, the US FDA approved five new indications for cancer management. Futibatinib for Metastatic Cholangiocarcinoma. Accelerated approval was granted for the...

FDA Approved 3 New Indications in Oncology in June-July 2022

FDA Approved 3 New Indications in Oncology in June-July 2022

The US FDA approved three new indications for cancer management between 1 June and 31 July, 2022. Dabrafenib Plus Trametinib for BRAF...

Intensive Follow-up Does Not Improve Survival in Endometrial Cancer

Intensive Follow-up Does Not Improve Survival in Endometrial Cancer

Endometrial cancer is among the most common gynecological cancers in Europe. Fortunately, most patients present with operable disease which has a good...

Adjuvant Toripalimab vs. High-Dose Interferon in Mucosal Melanoma: Similar Efficacy, Better Tolerability

Adjuvant Toripalimab vs. High-Dose Interferon in Mucosal Melanoma: Similar Efficacy, Better Tolerability

Mucosal melanoma (MM) is rare in the West, but in Asia it is the second most common melanoma subtype, accounting for about...